 |
| Anno II | Numero 11 | Marzo 2017 |
| Comitato scientifico editoriale: Massimo Di Maio, Silvia Novello Editore: Intermedia – Direttore Responsabile: Mauro Boldrini |
| Notizie dalla ricerca |
Immune checkpoint inhibitors in first-line therapy of advanced non-small cell lung cancer |
| Evading immune destruction is a hallmark of cancer. The first therapeutic wave in immunotherapies comprised a series of monoclonal antibodies directed against the immune checkpoint molecules cytotoxic T-lymphocyte-associated protein 4, programmed death 1 (PD-1), and programmed death ligand-1 (PD-L1) revolutionizing the therapeutic landscape of advanced non-small cell lung cancer. They were validated initially as second-line treatment, becoming the new standard of care. Based on immunotherapies … |
| Continua a leggere |
| PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer |
| The expression of programmed death (PD) ligand 1 (PD-L1) protein expression assessed by immunohistochemistry (IHC) has been correlated with response and survival benefit from anti-PD-1/PD-L1 immune checkpoint inhibitor therapies in advanced non-small cell lung carcinoma (NSCLC). The efficacy of several agents appears correlated with PD-L1 expression. It remains controversial whether PD-L1 is prognostic in NSCLC. We assessed the prognostic value of PD-L1 IHC and its … |
| Continua a leggere |
| Evolution of Neoantigen Landscape During Immune Checkpoint Blockade in Non-Small Cell Lung Cancer |
| Immune checkpoint inhibitors have shown significant therapeutic responses against tumors containing increased mutation-associated neoantigen load. We have examined the evolving landscape of tumor neoantigens during the emergence of acquired resistance in non-small cell lung cancer patients after initial response to immune checkpoint blockade with anti-PD1 or anti-PD-1/anti-CTLA4 antibodies. Analyses of matched pretreatment and resistant tumors identified genomic … |
| Continua a leggere |
| Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: implications for assessment by small biopsy |
| Predicting response to checkpoint blockade therapy for lung cancer has largely focused on measuring programmed death-ligand 1 (PD-L1) expression on tumor cells. PD-L1 expression is geographically heterogeneous within many tumors, however, and we questioned whether small tissue samples, such as biopsies, might be sufficiently representative of PD-L1 expression for evaluating this marker in lung cancer tumors. To evaluate the extent of variability of PD-L1 expression … |
| Continua a leggere |
| Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial |
| Atezolizumab is a humanised antiprogrammed death-ligand 1 (PD-L1) monoclonal antibody that inhibits PD-L1 and programmed death-1 (PD-1) and PD-L1 and B7-1 interactions, reinvigorating anticancer immunity. We assessed its efficacy and safety versus docetaxel in previously treated patients with non-small-cell lung cancer. We did a randomised, open-label, phase 3 trial (OAK) in 194 academic or community oncology centres in 31 countries. We enrolled patients who had squamous or … |
| Continua a leggere |
| Appuntamenti AIOM |
pd-L1: Un riferimento emergente nell’immuno-oncologia |
| Bari, 18 marzo 2017 Napoli, 23 marzo 2017 Aci Castello (CT), 25 marzo 2017 Parma, 12 aprile 2017 |
| Pink Lung Cancer 3 Diagnosi e terapia nel NSCLC: discutere con esperti in rosa |
| Bari, 23 marzo 2017 |
| Neoplasie della mammella e del polmone Aggiornamenti classificativi e citogenetico-molecolari |
| Roma, 24 marzo 2017 |
| La presa in carico globale del paziente oncologico: tra appropriatezza, innovazione e sostenibilità |
| Patrocinio concesso dalla Sezione Regionale AIOM Lombardia Pavia, 24 marzo 2017 |
| Immunoterapia nei Tumori del Polmone e dell’Urotelio A che punto siamo? |
| Roma, 27 – 28 marzo 2017 |
| Top Thoracic Oncology Padova Non-Small Cell Lung Cancer: Focus on Oligometastatic Disease and 2017 Update |
| Padova, 31 marzo – 1 aprile 2017 |
| Approccio multidisciplinare nel trattamento del microcitoma polmonare: tra tradizione e prospettive future |
| Roma, 31 marzo 2017 |
| Workshop Immuno-Oncologia |
| Padova, 7 – 8 aprile 2017 |
| DOMINO Workshop DecisiOn Making IN Oncology |
| Milano, 12 aprile 2017 Roma, 22 maggio 2017 |
| La Real World Evidence in Italia: stato dell'arte e prospettive Seconda edizione |
| Roma, 27 aprile 2017 |
| OXYMORON Elderly Young in Lung Cancer |
| Milano, 5 maggio 2017 |
| Focus On: Terapie innovative in oncologia |
| Pistoia, 12 maggio 2017 |
| Innovazione e nanomedicina al servizio del paziente oncologico anziano |
| Catania, 18 maggio 2017 |
| Il lato nascosto dell’evidenza Ricerca Scientifica e Decisioni Terapeutiche in Oncologia |
| Verona, 23 maggio 2017 |
| XI National Congress of the Italian Society of Immunology, Clinical Immunology and Allergology |
| Bari, 28 -31 maggio 2017 |
| Questi e altri appuntamenti si possono consultare sul sito AIOM www.aiom.it |
| Editore: Intermedia s.r.l. – Via Malta 12/b, 25124 Brescia – tel. 030 226105 fax 030 2420472 – Reg. Trib. di Brescia n. 35/2001 del 2/7/2001 Per contattare la redazione e commentare le notizie clicca qui: redazione Per consultare i numeri arretrati della newsletter clicca qui: archivio Per sospendere la ricezione di questa newsletter clicca qui: AIOM news RIMUOVI |
Questo progetto è stato realizzato con il contributo incondizionato di  |